Using advanced MRI to understand how Filgotinib relieves pain in rheumatoid arthritis
Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
This study is testing how Filgotinib helps relieve pain in people with rheumatoid arthritis by looking at brain activity and inflammation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 74 Years |
| Sex | All |
| Sponsor | NHS Greater Glasgow and Clyde Academic / other |
| Drugs / interventions | filgotinib, baricitinib, tofacitinib |
| Locations | 1 site (Glasgow) |
| Trial ID | NCT05697159 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the mechanisms behind the analgesic effects of Filgotinib in patients with rheumatoid arthritis (RA). By utilizing 7 Tesla MRI brain imaging, the researchers will investigate how central nervous system pathways and peripheral inflammation contribute to pain relief. The study will focus on patients who have been prescribed Filgotinib, assessing both brain connectivity and inflammatory markers to better understand the rapid onset of pain relief associated with this treatment. The findings could provide insights into the complex nature of pain in RA and improve therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 with moderate to severe active rheumatoid arthritis who have been prescribed Filgotinib.
Not a fit: Patients with severe physical impairments, major neurological diseases, or contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of pain management in rheumatoid arthritis, potentially improving treatment outcomes for patients.
How similar studies have performed: While studies on JAKinibs have shown promising results in pain management, this specific approach using advanced MRI to decipher mechanisms is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are: * Adults ≥18 years \< 75 years. * Right-handed (to reduce neuroimaging heterogeneity). Exclusion Criteria: * Inability to provide written informed consent. * Severe physical impairment (e.g. blindness, deafness, paraplegia). * Pregnant or breast feeding. * Severe claustrophobia precluding MRI. * Contraindications to MRI. * Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury. * Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.
Where this trial is running
Glasgow
- Neil Basu — Glasgow, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Neil Basu, MD, PhD — University of Glasgow
- Study coordinator: Maxine Arnott
- Email: maxine.arnott@glasgow.ac.uk
- Phone: 0141 330 8388
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.